At the end of the 299th MPC meeting on Thursday, the committee was unanimous in its decision to hold all parameters and thus decided to retain the MPR at 27.50 per cent, the asymmetric corridor ...

Findings from the phase 1b Beamion LUNG-1 trial showed an objective response rate of 71% in NSCLC patients treated with zongertinib. The Food and Drug Administration (FDA) has granted Priority ...

A follow-up question was not answered. MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible ...

MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all. Those interested in running will ...

The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled bleeding or in those who require urgent surgery or invasive procedure ...

We aim to build confidence in the safety and reliability of payment service providers’ services while protecting end users from specific risks.